Evidence Grade A — Regulatory approved. 855 published studies. 35 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Dalbavancin (sold as Dalvance) is an intravenous antibiotic with a remarkably long duration of action — a single infusion provides therapeutic antibiotic levels for over two weeks. This makes it possible to treat serious bacterial skin infections with just one hospital visit instead of days of intravenous therapy. It is also being studied for bone and joint infections, where patients would otherwise need weeks of daily IV antibiotics.
Dalbavancin is also known by these brand and alternate names:
855 published studies: 545 human, 20 animal, 152 in-vitro, 265 reviews
Dalbavancin is marketed as Dalvance (approved May 2014). Originally approved as a two-dose regimen (Day 1 and Day 8), a single-dose regimen was approved in January 2016, and paediatric approval followed in 2021. Indicated for ABSSSI caused by susceptible gram-positive organisms.
Dalbavancin's 346-hour half-life is the longest of any approved antibiotic, and there is growing off-label interest in its use for conditions requiring prolonged antibiotic courses, such as osteomyelitis and prosthetic joint infections — conditions where patients would otherwise need weeks of daily intravenous antibiotics. The DOTS trial (2025) showed non-inferiority to standard-of-care antibiotics for bone and joint infections, potentially expanding its clinical role significantly.
Dalbavancin works through the same fundamental mechanism as vancomycin — blocking cell wall construction by binding the D-Ala-D-Ala target on peptidoglycan precursors. However, its fatty acid chain anchors it to the bacterial membrane, concentrating the drug at exactly the site where cell wall assembly occurs. This anchoring effect, combined with the ability to form pairs (dimers) at the membrane surface, makes dalbavancin approximately 16 times more potent than vancomycin against MRSA in laboratory testing.
Dalbavancin's evidence for skin infections is solid, based on three Phase III trials with over 1,300 patients. Its 346-hour half-life is the longest of any approved antibiotic. The drug was initially approved as a two-dose regimen but a single-dose option followed in 2016, and paediatric approval came in 2021. The most clinically exciting development is its potential for bone and joint infections. A major trial (DOTS, published in 2025) showed dalbavancin was non-inferior to standard antibiotics for these infections — conditions that typically require prolonged IV antibiotic courses through a central line. If this use gains widespread adoption, it could fundamentally change how bone and joint infections are managed. Side effects are generally mild, though liver enzyme elevations and allergic reactions can occur.
PeptideTrace tracks 35 registered clinical trials for Dalbavancin sourced from ClinicalTrials.gov.
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
Efficacy and Safety of Dalbavancin As Suppressive Therapy
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
FDA ORIG 1
FDA SUPPL 1
EMA Marketing Authorisation
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 4
FDA SUPPL 7
Health Canada Market Authorisation
FDA SUPPL 10
FDA SUPPL 12
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
Dalbavancin is a semisynthetic lipoglycopeptide from A-40926 (Nonomuraea sp.), heptapeptide core, MW 1,816.7 Da. C12 fatty acid chain (10-methylundecanoyl), amidated carboxyl group, two chlorine atoms. Lipophilic side chain enables membrane anchoring and dimerization. IV over 30 min: single 1,500 mg or two-dose (1,000 mg Day 1, 500 mg Day 8). Half-life ~346 hours (~14.4 days). Protein binding ~93%.
Binds D-Ala-D-Ala termini of lipid II, blocking transglycosylation and transpeptidation. C12 fatty acid chain produces 16-fold greater potency than daptomycin and 32-fold greater than vancomycin against MRSA in vitro. Dimerization at membrane surface concentrates drug at peptidoglycan biosynthesis site, dramatically increasing binding affinity.
Marketed as Dalvance (US)/Xydalba (EU). Approved May 23, 2014 (first QIDP under GAIN Act). Single-dose approved January 21, 2016; pediatric July 23, 2021. DISCOVER 1 (N=573): 83.3% vs. 81.8%. DISCOVER 2 (N=739): 76.8% vs. 78.3%. DUR001-303 (N=698): single dose non-inferior to two-dose. DOTS (JAMA 2025; N=200): non-inferior but not superior for S. aureus bacteremia. Indication: ABSSSI from birth.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Comparisons
Evidence Reviews
Timelines
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
